Ascletis Pharma Inc. (HKG:1672)
10.25
+0.43 (4.33%)
Aug 20, 2026, 4:09 PM HKT
Ascletis Pharma Stock Forecast
Stock Price Forecast
According to 3 analysts polled by S&P Global, Ascletis Pharma stock has a consensus rating of "Buy" and an average price target of $23.95. The average 1-year stock price forecast is 133.66% higher than the current stock price, while the lowest is $15.76 (+53.76%) and the highest is $32.13 (+213.46%).
Price Target: $23.95 (+133.66%)
Analyst Consensus: Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Ascletis Pharma stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Mar '26 | Apr '26 | May '26 | Jun '26 | Jul '26 | Aug '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 1 | 1 | 1 | 1 |
| Buy | 1 | 0 | 0 | 0 | 0 | 1 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 3 | 2 | 2 | 2 | 3 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
Unknown Analyst Orient Securities No rating | Orient Securities | Buy Maintains $12.19 → $13.83 | Buy | Maintains | $12.19 → $13.83 | +34.93% | Aug 14, 2026 |
Unknown Analyst Goldman Sachs No rating | Goldman Sachs | Hold Maintains $13.76 → $15.71 | Hold | Maintains | $13.76 → $15.71 | +53.27% | Apr 3, 2026 |
Financial Forecast
Revenue This Year
536.92M
from 2.03M
Increased by 26,375.18%
Revenue Next Year
69.01M
from 536.92M
Decreased by -87.15%
EPS This Year
n/a
EPS Next Year
n/a
Financial currency is CNY.